Abstract:
Are you currently involved in the development of AAV-based gene therapy, specifically with non-human primates (NHP) or other large animals? Whether your focus is on constructing disease models or conducting pre-IND safety and toxicity studies, there are significant challenges associated with preclinical NHP or large animal studies for AAV-based gene therapy.
Explore solutions to challenges like high costs, low consistency, toxicity to animals, and immune responses due to AAV impurities. Learn how highly purified AAV enhances safety, efficacy, and data reproducibility. Delve into discussions on how rigorous standards, such as precise titer measurements, AAV genome integrity, Capsid characterization, impurity control, and safety measures minimize confounding factors and elevate the accuracy of your study.
On-demand video
Time:
Speaker:
Name: Irene Song
Company: PackGene Biotech
Title: Sr. Director, Global Product
Biography
Related services:
AAV Packaging (NHP Grade)
READ MORE
